Search Results for: casgevy

Weekly reads: Verve Therapeutics, Casgevy UK OK, GDNF, MYC

Sekar Kathiresan, Verve Therapeutics

Some folks can view data from early, small clinical trials too skeptically or overly enthusiastically, and maybe that’s going on with some preliminary results from Verve Therapeutics. Good news? Bad news? I’m going to start with two articles about the same news that have very different vibes. What do I think? On the whole, I […]

Weekly reads: Verve Therapeutics, Casgevy UK OK, GDNF, MYC Read More »

Recommended reads: 3 infected in Mexico, stem cell hype, hearing restoration

muscle stem cell hype

Stem cell hype is a big problem these days. It’s been going on for decades. Even some generally good citizens of the stem cell and regenerative medicine arena engage in it at times. Maybe a few of them don’t even realize what they are doing. I think a few journalists occasionally fall into the hype

Recommended reads: 3 infected in Mexico, stem cell hype, hearing restoration Read More »

Recent stem cell & regenerative medicine good news

stem cell good news, good news

Looking for some stem cell good news? You’ll like today’s post. One mission of this blog The Niche is to promote rigorous science-based regenerative medicine, which can lead to investigating and writing about not-so-upbeat stuff. Risky clinics. People getting hurt. Patient lawsuits. Serious FDA, FTC, or state AG regulatory developments. Such actions can be good

Recent stem cell & regenerative medicine good news Read More »

20 stem cell & regenerative medicine predictions for 2024

Stem cell, crystal ball, predictions

Each year I make predictions for the stem cell and regenerative medicine field for the following year. Today’s prediction post is focused on what to expect in 2024. You can also see my stem cell predictions for 2023 and my grades on how I did. I also have made a video version of these predictions so please

20 stem cell & regenerative medicine predictions for 2024 Read More »

New Year’s reads: having a blastema, gene therapy cost, pathogen lab escape data

blastema

Years ago I wrote about how I wished humans could form a blastema, which is a special area of regeneration near an injury that drives tissue replacement. For example, when a lizard loses its tail to a pursuing bobcat, if it can regrow a new one that process will depend on a blastema. The same goes

New Year’s reads: having a blastema, gene therapy cost, pathogen lab escape data Read More »

2023 stem cell predictions grades reflect wild year for regenerative medicine

stem cell predictions

Every year I make stem cell and regenerative medicine predictions. Looking at my predictions for 2023, they reflect a wild year but in many ways a good one overall. Below I have graded my 2023 predictions. Overall, my crystal ball gave solid results. Some of the predictions have been condensed to keep things concise, but you

2023 stem cell predictions grades reflect wild year for regenerative medicine Read More »

Weekly reads: FDA OKs 2 gene therapies for sickle cell, new Paolo Macchiarini series, Fujifilm

Marie Tornyenu, Casgevy gene therapies for sickle cell

The big news broke Friday that the FDA approved two new gene therapies for sickle cell disease. While the approvals were expected and the actual use of these treatments will be complex on several levels, this is a historic development. 2 FDA-approved gene therapies for sickle cell Friday’s news follows on recent UK approval for

Weekly reads: FDA OKs 2 gene therapies for sickle cell, new Paolo Macchiarini series, Fujifilm Read More »